Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Acq. announced
Director departure
Inv. presentation
Quarterly results
Consulting agrmnt
Appointed COO
Appointed director
CC transcript

BIOGEN INC. (BIIB) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/28/2021 GN Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
04/28/2021 GN Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
04/19/2021 GN Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
04/07/2021 GN The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
03/04/2021 GN Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
02/24/2021 GN Life Science Cares and Biogen Foundation Help Launch Food For Free's Just Eats Program
02/11/2021 GN Biogen Announces the Expiration Date Results of Its Cash Tender Offer
02/11/2021 GN Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
02/10/2021 GN Biogen Announces the Pricing Terms of its Cash Tender Offer
02/10/2021 GN Biogen Announces the Pricing Terms of Its Private Exchange Offer
02/04/2021 GN Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
02/01/2021 GN Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
01/29/2021 GN Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
01/11/2021 GN BIIB FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
01/11/2021 GN DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
01/11/2021 GN Portnoy Law: Lawsuit Filed On Behalf of Biogen, Inc. Investors
01/11/2021 GN Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/08/2021 GN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
01/08/2021 GN Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/06/2021 GN TILE, BIIB & BABA Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
01/05/2021 GN BIIB INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc.
01/05/2021 GN ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
01/04/2021 GN DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12/29/2020 GN Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Interface, Cabot Oil & Gas, Biogen, and Stride and Encourages Investors to Contact the Firm
12/29/2020 GN DEADLINE ALERT for BABA, BIIB, YY, LRN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
12/28/2020 GN Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)
12/28/2020 GN TILE, BIIB & BABA Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
12/22/2020 GN Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Stride, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
12/22/2020 GN ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB
12/22/2020 GN DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12/21/2020 GN The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/20/2020 GN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
12/17/2020 GN DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12/16/2020 GN Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabot Oil & Gas, Biogen, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy